Bryant E. Fong
Managing Director @ Biomark Capital
San Francisco, United States
Bryant E. Fong is a funding round investor at Biomark Capital in San Francisco focused on Biotechnology and Health Care. Mr. Fong is a founding Managing Director at Biomark Capital, a life sciences private equity fund formed in 2013.Prior to BioMark Capital, Mr. Fong was a Managing Director and General Partner at Burrill & Company, where he spent almost 16 years investing in and managing investments in private and public companies in the biotechnologyindustry. Some of Mr. Fong's most notable investments include Pharmasset (VRUS), Novadaq Technologies (NVDQ), Galapagos (GLPG), Morphotek, Ceptaris Therapeutics, and Ferrokin Biosciences. Prior to joining Burrill & Company,Mr. Fong held positions as a research scientist with two early stage biotechnology companies located in the San Francisco Bay Area. Mr. Fong currently serves on the Boards of Directors of a number of life science companies including NEOS Therapeutics, Neurotech Pharmaceuticals, ADMA Biologics (ADMA), Acusphere (ACUS), i2Dx, WaveTec Vision, JHL Biotech, and Nora Therapeutics.Mr. Fong earned his bachelor's degree with honors in Molecular and Cell Biology-Biochemistry from the University of California, Berkeley.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 25%
Last updated:
For AI agents: llms.txt
Industries Bryant E. Fong invests in
Stages Bryant E. Fong invests in
Countries Bryant E. Fong invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 6 (50%)
- Medical 4 (33%)
- Therapeutics 2 (17%)
- Pharmaceutical 2 (17%)
Stage
- Funding Round 4 (33%)
- Series B 3 (25%)
- Series A 1 (8%)
- Series C 1 (8%)
- Post-IPO Equity 1 (8%)
Country
- United States 7 (58%)
- Taiwan 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $106M / Post-IPO Equity / May 29, 2018 | |
Neos Therapeutics
|
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $20.6M / Venture - Series Unknown / Feb 19, 2015 | |
|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | $35M / Series B / Jun 19, 2014 | |
Nora Therapeutics
|
Nora Therapeutics is a specialty biopharmaceutical company focused on developing therapeutics to address clinical unmet needs in reproductive medicine.Nora’s lead compound, NT100, is a novel treatment being studied to improve pregnancy success rates and outcomes for women who have undergone multiple unsuccessful in vitro fertilization (IVF)procedures. NT100 is a novel biologic agent similar to a naturally occurring protein in the female reproductive tract. NT100’s mechanism of action may better enable embryo implantation and pregnancy maintenance by optimizing maternal-fetal immune tolerance. | $18M / Series B / Apr 17, 2014 | |
|
Neos Therapeutics
|
The Neos Therapeutics team is dedicated to creating high-quality products and partnering with pharmaceutical and consumer healthcare companies to address key medical needs.Neos Therapeutics’ research and development (R&D) and fully integrated state of the art, FDA approved manufacturing facility is located in the Dallas/Fort Wortharea. | $15.5M / Series C / Mar 04, 2014 | |
Odyssey Thera
|
Odyssey Thera, Inc., a biopharmaceutical company, develops cellular pharmacology strategy for the identification of medicines for human diseases. It focuses on the identification and development of treatment therapies for cancer. The company was formerly known as Odyssey Pharmaceuticals. Odyssey Thera, Inc. is based in San Ramon, California. | $2.8M / Feb 14, 2013 | |
|
Eden Biologics
|
Eden Biologics, formerly known as JHL Biotech ("JHL") , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development tocommercial manufacturing with both global and regional regulatory affairs expertise. | Series A / Dec 17, 2012 | |
i2Dx
|
i2Dx is developing a multimodal, cloud-based diagnostic platform for the assessment of neurological disorders. The platform will provide quantitative digital assessments of a number of biomarkers that are indicative of brain health with the goal of providing a personalized, longitudinal brain record for healthy individuals and patients. | Jul 17, 2012 | |
WaveTec Vision
|
WaveTec Vision is a small company with a big idea – and the ability and the team to achieve it. Their proprietary intraoperative aberrometer system ORange will transform and advance the emerging convergence of refractive and cataract surgery. It was founded in 1997 and headquartered in Aliso Viejo, California. | $16.5M / Apr 09, 2012 | |
ADMA Biologics
|
ADMA is a specialty immune globulin company that develops, manufactures and intends to market plasma-based biologics targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The Company’s target patient populations include immune-compromised individuals who suffer from an underlying immune deficiencydisease or who may be immune-suppressed for medical reasons.ADMA also operates ADMA BioCenters, FDA-licensed source plasma collection facilities which provide a portion of blood plasma for the manufacturing of the Company’s lead product candidate RI-002. | $17.5M / Feb 13, 2012 | |
| See all 12 investments → | |||
Co-Investors
About Biomark Capital
Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies. We target companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health that will change the face of healthcare innovation in the future. We share the drive and vision of our portfolio companies tocollaborate with them in accelerating growth and building successful business ventures.
Biomark Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna G. Annenko
Director
|
|||
|
Bryant E. Fong
Managing Director
|
|||
David Wetherell
Founder & Managing Director
|
|||
Douglas Lind
Managing Director
|
|||
Janos Redei
EIR
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Bryant E. Fong invest in?
Bryant E. Fong invests primarily in Biotechnology, Health Care and Medical startups, most often at Funding Round and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Bryant E. Fong?
Public channels for Bryant E. Fong include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bryant E. Fong last invest?
The most recent investment recorded for Bryant E. Fong closed in May 2018. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
